Announcements Trials
Browse Landscape

Status

Completed 15Withdrawn 3Unknown 3Available 3No longer available 2Active not recruiting 2Terminated 1Recruiting 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Recurrence 1Pheochromocytoma 1Paraganglioma 1Neoplasms 1

Interventions

gallium 68 PSMA-11 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2motexafin gadolinium 1glucarpidase 1Positron-Emission Tomography 1Leucovorin 1Laparoscopy 1Gemtuzumab 1Gadolinium 1Carboxypeptidases 1Amifampridine 13-Iodobenzylguanidine 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × OTHER × 3-Iodobenzylguanidine × Clear all
NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡